Table 1.
Patient and tumor characteristics
| Characteristic | Pts treated with sorafenib (N = 105) | Pts used to test the SSS (N=37) | ||
|---|---|---|---|---|
| No. | % | No. | % | |
| Gender | ||||
| Male | 54 | 51.4 | 21 | 56.8 |
| Female | 51 | 48.6 | 16 | 43.2 |
| Age, years | ||||
| < 60 | 43 | 41.0 | 17 | 45.9 |
| ≥ 60 | 62 | 59.0 | 19 | 54.1 |
| Race/Ethnicity | ||||
| White | 86 | 81.9 | 33 | 89.2 |
| Black | 7 | 6.7 | 2 | 5.4 |
| Hispanic | 7 | 6.7 | 0.0 | 0.0 |
| Asian | 5 | 4.8 | 2 | 5.4 |
| Smoking | ||||
| Current | 6 | 5.7 | 0.0 | 0.0 |
| Former | 73 | 69.5 | 31 | 83.8 |
| Never | 26 | 24.8 | 6 | 16.2 |
| ECOG performance status | ||||
| 0 | 6 | 5.7 | 2 | 5.4 |
| 1 | 87 | 82.9 | 30 | 89.2 |
| 2 | 12 | 11.4 | 5 | 5.4 |
| Histology | ||||
| Adenocarcinoma | 71 | 67.7 | 29 | 78.4 |
| Squamous cell carcinoma | 14 | 13.3 | 3 | 8.1 |
| NSCLC otherwise unspecified | 16 | 15.2 | 5 | 13.5 |
| Other | 4 | 3.8 | 0.0 | 0.0 |
| Number of prior treatments for stage IV disease | ||||
| 1 | 25 | 23.8 | 9 | 24.3 |
| 2 | 33 | 31.4 | 12 | 32.4 |
| 3 | 24 | 22.9 | 11 | 29.7 |
| 4 | 16 | 15.2 | 3 | 8.1 |
| ≥5 | 7 | 6.7 | 2 | 5.5 |
| Previous erlotinib | ||||
| Yes | 71 | 67.6 | 22 | 59.5 |
| No | 34 | 32.4 | 15 | 40.5 |
| Previous bevacizumab | ||||
| Yes | 43 | 41.0 | 15 | 40.5 |
| No | 62 | 59.0 | 22 | 59.5 |
| EGFR mutation | ||||
| No | 72 | 85.7 | 37 | 100 |
| Yes | 12# | 14.3 | 0 | 0.0 |
| EGFR gene copy number | ||||
| FISH negative | 70 | 84.3 | 32 | 86.5 |
| FISH positive | 13* | 15.7 | 5 | 13.5 |
| K-RAS mutation | ||||
| No | 65 | 77.4 | 30 | 81.1 |
| Yes | 19# | 22.6 | 7 | 18.9 |
| B-RAF mutation | ||||
| No | 80 | 95.2 | 37 | 100 |
| Yes | 4# | 4.8 | 0 | 0.0 |
#
among 84 patients with available data;
*
among 83 patients with available data;
Abbreviations: SSS: sorafenib sensitivity signature; ECOG, Eastern Cooperative Oncology Group; NSCLC: non-small cell lung